Osteosarcoma clinical trials provide participants with opportunities to access promising new bone cancer treatments that are not yet available in other settings. At the same time, medical experts can evaluate the effectiveness of these new therapies as compared to the current standard of care. If a new treatment proves to be more effective or equally effective with fewer side effects, it may become the new standard of care, advancing the treatment options for all current and future bone cancer patients.
The renowned research team at Moffitt Cancer Center continues to learn more about how osteosarcoma cells differ from healthy bone cells. As our knowledge base expands, we are constantly developing and refining our bone cancer treatment strategies based on new information, and we are evaluating new treatments through osteosarcoma clinical trials. For instance, our team is currently studying:
- Immunotherapy drugs, such as muramyl tripeptide, which are designed to help a patient’s immune system identify, target and destroy bone cancer cells
- Targeted therapy drugs, such as man-made immune system proteins (monoclonal antibodies), which attach to certain cancer cell proteins and destroy those cells or inhibit their growth
- Biophosphonate drugs, such as pamidronate and zoledronic acid, which affect bone cells (osteoclasts) that promote bone tissue growth and healing
- Inhalable chemotherapy drugs, such as cisplatin, that could help treat osteosarcomas that have spread to the lungs
The osteosarcoma clinical trials performed at Moffitt are overseen by a multispecialty team of bone cancer experts. Through careful monitoring, we ensure that every patient receives the best possible treatment for his or her specific needs as we continue to make important strides in beating this rare form of bone cancer. In recognition of our groundbreaking research, Moffitt has been designated a Comprehensive Cancer Center by the National Cancer Institute, and we are the only cancer center based in Florida to have earned this prestigious designation.
If you are interested in learning more about osteosarcoma clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Our team is experienced in matching patients with the clinical trials that are most likely to benefit them. Call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online.